RhumbLine Advisers’s DarioHealth DRIO Stock Holding History

RhumbLine Advisers’s Portfolio DRIO Stock Details DRIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-769	Closed	-$90K	–	3134
2022 Q1	$90K	Buy	769 +27	+4%	+$4.47K	﹤0.01%	2904
2021 Q4	$193K	Sell	742 -24	-3%	-$7.3K	﹤0.01%	2841
2021 Q3	$209K	Buy	766 +32	+4%	+$9.23K	﹤0.01%	2901
2021 Q2	$314K	Buy	+734	New	+$279K	﹤0.01%	2766

Other funds holding DRIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

CHM

Collaborative Holdings Management New York $49.2M AUM 119.38% 1-Year Est. Return

AWAM

Appian Way Asset Management New York $558M AUM 1.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's DRIO Position: Q2 2022 in Review

RhumbLine Advisers sold out of DarioHealth (DRIO) in Q2 2022, closing a stake of 769 shares — an estimated $90K sold.

RhumbLine Advisers first reported a position in DRIO in Q2 2021 and held it in 4 quarters. The position peaked at $314K in Q2 2021. 58 funds tracked by Wall St. Rank hold DRIO as of Q2 2022.

RhumbLine Advisers reported no remaining DarioHealth position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 769 DarioHealth shares in Q2 2022, an estimated $90K.
RhumbLine Advisers first reported a position in DarioHealth in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's DarioHealth position peaked at $314K in Q2 2021.
58 funds tracked by Wall St. Rank held DarioHealth as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.